Rocket Pharmaceuticals, Inc. (RCKT) Stock Price & Analysis
Rocket Pharmaceuticals, Inc. (RCKT) fell 1.85% to USD 2.65 as of June 10, 2026 at 03:44 UTC, according to Nexqual real-time market data.
RCKT last closed at USD 2.7; the session ranged USD 2.53–2.78 on volume of 2,683,365 shares. Market capitalization is $289.36M, with a 52-week range of USD 2.4–5.45 (NGM). Source: Nexqual, June 10, 2026 at 03:44 UTC.
Key Statistics (as of June 10, 2026 at 03:44 UTC)
| Price | USD 2.65 |
|---|---|
| Change | ▼ 1.85% (down) |
| Previous Close | USD 2.7 |
| Open | USD 2.72 |
| Day Range | USD 2.53 – 2.78 |
| 52-Week Range | USD 2.4 – 5.45 |
| Volume | 2,683,365 shares |
| Market Cap | $289.36M |
| Exchange | NGM |
Technical Analysis (RCKT)
Nexqual's technical model rates RCKT "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:44 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 26.35 (oversold) |
| vs SMA50 | Below (USD 3.39) |
| MACD | -0.21 (negative) |
Analyst Ratings (RCKT)
Wall Street analysts rate RCKT "Buy" based on 11 analysts, with a mean price target of USD 9.39 (range USD 3–16), per Nexqual as of June 10, 2026 at 03:44 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 9.39 |
| High Target | USD 16 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 5 / 6 / 2 |
Earnings (RCKT)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 0.35 |
| Revenue Estimate | $16.55M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.42 vs est -0.45 ▲ beat |
| 2025-12-31 | USD -0.38 vs est -0.42 ▲ beat |
| 2025-09-30 | USD -0.45 vs est -0.52 ▲ beat |
| 2025-06-30 | USD -0.59 vs est -0.53 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:44 UTC.
Financials & Fundamentals (RCKT)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -64.41% |
| Debt / Equity | 10.4 |
| Current Ratio | 6.12 |
| Total Cash | $144.38M |
| Total Debt | $24.76M |
| Free Cash Flow | $-98.86M |
Source: Nexqual, June 10, 2026 at 03:44 UTC.
Financial Health Score (RCKT)
Nexqual rates Rocket Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:44 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $144M cash vs $25M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$180M |
| Efficiency | Critical — ROE -64%, ROA -35.1% |
Ownership (RCKT)
| Insider Ownership | +2.97% |
|---|---|
| Institutional Ownership | +89.86% |
| Shares Outstanding | 109.19M |
| Float | 87.64M |
| Short % of Float | +25.23% |
Source: Nexqual, June 10, 2026 at 03:44 UTC.
Leadership (RCKT)
Rocket Pharmaceuticals, Inc. is led by Gaurav D. Shah (age 50), CEO & Director, per Nexqual as of June 10, 2026 at 03:44 UTC.
| CEO & Director | Gaurav D. Shah (age 50) |
|---|---|
| Chief Operating Officer | Christopher Stevens (age 44) |
| Senior Vice President & Head of External Affairs | Meg Dodge J.D., L.L.M. |
| Director of Corporate Communications | Kevin Giordano |
Major Backers & Investors (RCKT)
Notable institutional backers of Rocket Pharmaceuticals, Inc. include RTW Investments LP, Citigroup Inc., Maverick Capital Ltd., according to Nexqual as of June 10, 2026 at 03:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RTW Investments LP | 16.2% |
| Citigroup Inc. | 4.68% |
| Maverick Capital Ltd. | 3.27% |
| Newtyn Management, Llc | 2.9% |
| Millennium Management | 2.86% |
| Fidelity | 0.76% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 14.25% |
| BlackRock | 9.68% |
| State Street | 6.71% |
| Nuveen | 2.87% |
Source: Nexqual, June 10, 2026 at 03:44 UTC.
From Rocket Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States.
- It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red de Enfermedades Raras, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and Temple University.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ARVN | Arvinas, Inc. | USD 7.21 | ▼ 2.83% |
| RGNX | REGENXBIO Inc. | USD 6.34 | ▲ 4.28% |
| DNLI | Denali Therapeutics Inc. | USD 20.79 | ▲ 6.51% |
| REPL | Replimune Group, Inc. | USD 9.24 | ▼ 2.43% |
| KURA | Kura Oncology, Inc. | USD 8.81 | ▲ 0.8% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:44 UTC. This page is informational and not investment advice.